课题基金 / 基金详情

EFFECTS OF XENICAL ON LPL AND HTGL FOLLOWING A FAT RICH BREAKFAST

EFFECTS OF XENICAL ON LPL AND HTGL FOLLOWING A FAT RICH BREAKFAST
富含脂肪的早餐后赛尼可对 LPL 和 HTGL 的影响
批准号:
6245256
负责人:
Robert H Eckel
金额:
$2.65万
依托单位国家:
美国
项目类别:
财政年份:
1997
资助国家:
美国
项目状态:
已结题
起止时间:
1997-02-14 至 1997-11-30

项目摘要

项目成果

Robert H Eckel的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Xenical (orlistat) is a new anti-obesity drug which limits fat absorption by the inhibition of pancreatic lipase (PL) activity. Xenical may inhibit systemic plasma lipases as well as gastrointestinal lipases. The effect or lack thereof that Xenical or its metabolites have on lipoprotein lipase (LPL) and hepatic triglyceride lipase (HTGL) activity during the time triglycerides appear in the circulation after eating needs to be established. Therefore, the effects of Xenical and its metabolites on postprandial pre-and postheparin LPL and HTGL activities and on postprandial plasma lipoprotein concentrations were examined in this clinical trial.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
2018 Kern Lipid Conference
  • 批准号:
    9610114
  • 项目类别:
  • 资助金额:
    $1.95万
  • 财政年份:
    2018
  • 负责人:
    Robert H Eckel
  • 依托单位:
2017 Kern Lipid Conference
  • 批准号:
    9396189
  • 项目类别:
  • 资助金额:
    $1.0万
  • 财政年份:
    2017
  • 负责人:
    Robert H Eckel
  • 依托单位:
2015 Kern Lipid Conference
  • 批准号:
    8985457
  • 项目类别:
  • 资助金额:
    $1.0万
  • 财政年份:
    2015
  • 负责人:
    Robert H Eckel
  • 依托单位:
Obesity and Cardiovascular Disease: Opportunity for Post-Doctoral Training
  • 批准号:
    9293351
  • 项目类别:
  • 资助金额:
    $27.8万
  • 财政年份:
    2014
  • 负责人:
    Robert H Eckel
  • 依托单位:
海外基金